Long-Term Safety Monitoring

Short-term safety data cannot rule out late-emerging cancer risks linked to genomic integration. The safety implication is limited by the fact that the case is rare among thousands of treated patients. The rare case strengthens the rationale for long-term monitoring after gene therapy. Long-term surveillance remains necessary even for vector systems designed to avoid genome integration.